Tag: VEGFR-targeted therapy

Home / VEGFR-targeted therapy

Categories

Cabozantinib is approved for differentiated thyroid cancer

October 2021: Cabozantinib (Cabometyx, Exelixis, Inc.) has been approved by the Food and Drug Administration for adult and paediatric patients 12 years of age and older who have locally advanced or me...
vegfr-targeted-therapy

Scan the code